CClinicalTrials.gg
CompletedNCT05580406Updated May 1, 2026Results posted

Outreach to Reduce Depression Disparities

An interventional study of Outreach messaging in Depression, sponsored by Kaiser Permanente. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Kaiser Permanente · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
309
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Previous research by Mental Health Research Network (MHRN) investigators and others demonstrates that online messaging and other telehealth technologies can effectively and efficiently address premature discontinuation of depression treatment. These interventions, however, have focused on adherence after treatment initiation and have been tested primarily in non-Hispanic white populations. Less is known about the acceptability and effectiveness of different communication modalities (online messaging, mailed letters, telephone) among racial and ethnic minority populations. Implementation of electronic-Health (eHealth) technologies must take care not to exacerbate health disparities.

This clinical trial involves a pilot trial to evaluate a population-based outreach program to improve rates of depression treatment initiation among traditionally underserved racial and ethnic groups. This pilot work intends to inform a subsequent full-scale pragmatic trial to examine impact on health disparities.

02

Conditions studied

  • Depression

Browse trials for

03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's enrollment of 309 is above the median of 84 across 6,720 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Kaiser Permanente is the lead sponsor of 385 studies on the registry; 41 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • New diagnosis of major depressive disorder or dysthymic disorder at a primary care visit ("new" defined as no depression diagnosis, psychotherapy visit or filled antidepressant prescription in the prior year)
  • Continuously enrolled in the participating health system for 365 days prior to the eligible diagnosis (to assure capture of prior diagnoses or treatments)
  • Patients Health Questionnaire-9 (PHQ-9) depression score of 10 or more within 14 days before to 7 days after the eligible diagnosis
  • No filled prescription for any antidepressant medication OR psychotherapy visit attended within 30 days of the eligible diagnosis*
  • No recorded PHQ-9 depression score less than 5 since the eligible diagnosis
  • At least 18 years of age or older

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of schizophrenia or bipolar disorder in the prior 2 years
  • Not registered to use Electronic Health Record (EHR) patient portal
  • Previously requested to not be contacted for research
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
309 participants (actual)

Study arms

  • No intervention
    Usual Care

    Participants assigned to usual care will not receive outreach messages (online or via telephone) by study staff.

  • Experimental
    Outreach Messaging

    Participants in the outreach messaging arm will receive messages via online secure message system (embedded within the health care record) and/or telephone.

    Behavioral: Outreach messaging

Interventions

  • BehavioralOutreach messaging

    Participants will receive outreach messages via health care system secure messaging and/or phone following a new diagnosis of depression made in primary care if the participant has failed to initiate treatment (pharmacotherapy or psychotherapy) within 30 days of new diagnosis.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Initiation of Formal Depression Treatment

    Defined as either at least one filled prescription for any antidepressant medication or attending at least one individual psychotherapy visit.

    Time frame: within 60 days of randomization

07

Results

Posted May 1, 2026

Participant flow

Participant flow — Overall Study
MilestoneUsual CareOutreach Messaging
Started152157
Completed152113
Not completed044
Withdrew: Did not read message or was not reached via telephone044

Outcome measures

PrimaryNumber of Participants With Initiation of Formal Depression Treatment

Defined as either at least one filled prescription for any antidepressant medication or attending at least one individual psychotherapy visit.

Time frame:
within 60 days of randomization
Reported as:
Count of participants · Participants
Number of Participants With Initiation of Formal Depression Treatment
ParticipantsUsual CareOutreach Messaging
Number of Participants With Initiation of Formal Depression Treatment936

Adverse events

Collected over Adverse event data were collected from randomization to 60-days post-randomization.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Usual Care0/152 (0%)0/152 (0%)0/152 (0%)
Outreach Messaging0/157 (0%)0/157 (0%)0/157 (0%)

Baseline characteristics

Individuals randomly assigned to usual care or outreach messaging

Age, Continuous
Age, Continuous(years)Usual CareOutreach MessagingTotal
Mean49.8 ± 19.549.5 ± 19.349.7 ± 19.4
Sex: Female, Male
Sex: Female, Male(Participants)Usual CareOutreach MessagingTotal
Female98109207
Male5448102
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Usual CareOutreach MessagingTotal
American Indian or Alaska Native011
Asian373067
Native Hawaiian or Other Pacific Islander172138
Black or African American5660116
White549
More than one race363874
Unknown or Not Reported134
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Usual CareOutreach MessagingTotal
Hispanic or Latino81220
Not Hispanic or Latino144145289
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Usual CareOutreach MessagingTotal
United States152157309
PHQ-9 total score
PHQ-9 total score(units on a scale)Usual CareOutreach MessagingTotal
Mean14.5 ± 4.213.9 ± 3.614.2 ± 3.9
08

Study locations

2 sites
  • Kaiser Permanente, Hawaii Market
    Honolulu, Hawaii 96817, United States
  • Henry Ford Health
    Detroit, Michigan 48202, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Aug 25, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05580406
Lead sponsor
Kaiser Permanente
Collaborators
Henry Ford Health System
Responsible party
Sponsor
First posted
Oct 14, 2022
Start date
Apr 13, 2023
Primary completion
Dec 10, 2024
Completion
Dec 10, 2024
Results posted
May 1, 2026
Last update
May 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion